Publications by authors named "P Desvigne-Nickens"
Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition that can lead to atrial fibrillation, heart failure, and sudden cardiac death in many individuals but mild clinical impact in others. The mechanisms underlying this phenotypic heterogeneity are not well defined. The aim of this study was to use plasma proteomic profiling to help illuminate biomarkers that reflect or inform the heterogeneity observed in HCM.
View Article and Find Full Text PDFArticle Synopsis
- - The SPIRRIT-HFpEF trial aims to evaluate the benefits of mineralocorticoid receptor antagonists (MRAs) like spironolactone for patients with heart failure and preserved or mildly reduced ejection fraction, focusing on a cost-effective registry-based approach.
- - This multicenter trial involves randomizing patients to receive either MRAs with usual care or just usual care, measuring outcomes such as cardiovascular deaths and heart failure-related hospitalizations over a 6-year enrollment period, with a target of around 2400 patients.
- - The study’s findings will provide insights into the effectiveness of MRAs for heart failure patients and demonstrate the viability of using pragmatic, registry-based trials for research in chronic conditions.
Article Synopsis
- The TRANSFORM-HF trial found no significant differences in outcomes between torsemide and furosemide for patients hospitalized with heart failure, with concerns about patient adherence affecting results.
- This study analyzed on-treatment outcomes, excluding non-adherent patients, assessing 2859 hospitalized heart failure patients over 12 months.
- The findings showed no notable differences in all-cause mortality or hospitalization rates between the two medications at discharge and 30-day follow-up.
Importance: Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years.
View Article and Find Full Text PDF